Agilent Technologies, Inc. A
We take great care to ensure that the data presented and summarized in this overview for AGILENT TECHNOLOGIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding A
View all-
Vanguard Group Inc Valley Forge, PA29.9MShares$4.61 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY26.9MShares$4.15 Billion0.09% of portfolio
-
Massachusetts Financial Services CO Boston, MA14.3MShares$2.2 Billion0.65% of portfolio
-
State Street Corp Boston, MA12.7MShares$1.95 Billion0.08% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.2MShares$1.57 Billion0.9% of portfolio
-
Wellington Management Group LLP Boston, MA9.42MShares$1.45 Billion0.25% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.54MShares$1.32 Billion0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA6.82MShares$1.05 Billion0.09% of portfolio
-
Pictet Asset Management Sa Geneva 73, V86.64MShares$1.02 Billion0.96% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V85.29MShares$817 Million0.86% of portfolio
Latest Institutional Activity in A
Top Purchases
Top Sells
About A
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Insider Transactions at A
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 08
2024
|
Simon May Senior Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
4,235
+50.0%
|
$601,370
$142.8 P/Share
|
May 03
2024
|
Henrik Ancher Jensen Sr Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
132
-0.16%
|
$18,348
$139.45 P/Share
|
Mar 25
2024
|
Philip Binns Senior Vice President |
SELL
Open market or private sale
|
Direct |
2,827
-22.04%
|
$415,569
$147.54 P/Share
|
Mar 15
2024
|
Sue H. Rataj Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+5.93%
|
$246,666
$147.48 P/Share
|
Mar 15
2024
|
George A Scangos Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+7.09%
|
$246,666
$147.48 P/Share
|
Mar 15
2024
|
Dow R Wilson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+9.42%
|
$246,666
$147.48 P/Share
|
Mar 15
2024
|
Mikael Dolsten Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+22.71%
|
$246,666
$147.48 P/Share
|
Mar 15
2024
|
Boon Hwee Koh Director |
SELL
Payment of exercise price or tax liability
|
Direct |
504
-0.83%
|
$74,088
$147.48 P/Share
|
Mar 15
2024
|
Boon Hwee Koh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+2.69%
|
$246,666
$147.48 P/Share
|
Mar 15
2024
|
Heidi Fields Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,678
+2.88%
|
$246,666
$147.48 P/Share
|
Mar 15
2024
|
Daniel K Podolsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,088
+2.85%
|
$306,936
$147.48 P/Share
|
Mar 15
2024
|
Mala Anand Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+11.65%
|
$246,666
$147.48 P/Share
|
Mar 15
2024
|
Hans Edgar Bishop Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,428
+4.7%
|
$356,916
$147.48 P/Share
|
Mar 15
2024
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,428
+13.6%
|
$356,916
$147.48 P/Share
|
Mar 08
2024
|
Michael R. Mc Mullen CEO and President |
SELL
Open market or private sale
|
Direct |
52,297
-17.08%
|
$7,844,550
$150.0 P/Share
|
Mar 07
2024
|
Rodney Gonsalves V.P., Corporate Controller |
SELL
Open market or private sale
|
Direct |
4,828
-18.46%
|
$719,372
$149.0 P/Share
|
Mar 05
2024
|
Heidi Fields Director |
SELL
Open market or private sale
|
Indirect |
1,658
-2.93%
|
$238,752
$144.34 P/Share
|
Mar 01
2024
|
Angelica Riemann Senior Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
880
+5.51%
|
$122,320
$139.06 P/Share
|
Mar 01
2024
|
Padraig Mcdonnell Sr. Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
3,202
+10.49%
|
$445,078
$139.06 P/Share
|
Dec 27
2023
|
Philip Binns Senior Vice President |
SELL
Open market or private sale
|
Direct |
2,880
-18.34%
|
$400,320
$139.78 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 285K shares |
---|---|
Exercise of conversion of derivative security | 77.9K shares |
Open market or private purchase | 2 shares |
Payment of exercise price or tax liability | 84.2K shares |
---|---|
Open market or private sale | 162K shares |